Abstract
Anhedonia, characterized by a loss of interest and/or pleasure in previously enjoyable activities, is an important diagnostic criterion of Major Depressive Disorder (MDD). Converging evidence implicates a causal relationship between proinflammatory cytokines and behavioural disturbances that characterize anhedonia in the context of MDD. Additionally, anhedonia has been implicated in disturbances of key central dopaminergic modulatory pathways. Emerging research into the roles of tetrahydrobiopterin, a cytokine-targeted co-enzyme in the synthesis of dopamine, and kynurenine, a product of inflammation-sensitive breakdown of tryptophan via indoleamine 2, 3-dioxygenase, have shed new light into the role of inflammation in mediating anhedonic behaviours. The following narrative review is not meant to be comprehensive, but highlights the roles of both tetrahydrobiopterin and kynurenine pathways in anhedonia, and discusses a potential mechanism of action via oxidative stress and excitotoxicity. Treatment implications are discussed, with an emphasis on anti-inflammatories as complements to current treatments of anhedonia and MDD.
Keywords: Anhedonia, Major Depressive Disorder (MDD), inflammation, tetrahydrobiopterin, kynurenine pathway, cytokines, oxidative stress, treatment implications.
Current Pharmaceutical Design
Title:Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD
Volume: 23 Issue: 14
Author(s): Zihang Pan, Joshua D. Rosenblat, Walter Swardfager and Roger S. McIntyre*
Affiliation:
- Professor of Psychiatry and Pharmacology, University of Toronto, Head, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street - Toronto, ON,Canada
Keywords: Anhedonia, Major Depressive Disorder (MDD), inflammation, tetrahydrobiopterin, kynurenine pathway, cytokines, oxidative stress, treatment implications.
Abstract: Anhedonia, characterized by a loss of interest and/or pleasure in previously enjoyable activities, is an important diagnostic criterion of Major Depressive Disorder (MDD). Converging evidence implicates a causal relationship between proinflammatory cytokines and behavioural disturbances that characterize anhedonia in the context of MDD. Additionally, anhedonia has been implicated in disturbances of key central dopaminergic modulatory pathways. Emerging research into the roles of tetrahydrobiopterin, a cytokine-targeted co-enzyme in the synthesis of dopamine, and kynurenine, a product of inflammation-sensitive breakdown of tryptophan via indoleamine 2, 3-dioxygenase, have shed new light into the role of inflammation in mediating anhedonic behaviours. The following narrative review is not meant to be comprehensive, but highlights the roles of both tetrahydrobiopterin and kynurenine pathways in anhedonia, and discusses a potential mechanism of action via oxidative stress and excitotoxicity. Treatment implications are discussed, with an emphasis on anti-inflammatories as complements to current treatments of anhedonia and MDD.
Export Options
About this article
Cite this article as:
Pan Zihang, Rosenblat D. Joshua, Swardfager Walter and McIntyre S. Roger*, Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD, Current Pharmaceutical Design 2017; 23 (14) . https://dx.doi.org/10.2174/1381612823666170111144340
DOI https://dx.doi.org/10.2174/1381612823666170111144340 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Should we Try to Alleviate Immunosenescence and Inflammaging - Why, How and to What Extent?
Current Pharmaceutical Design Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets NO-Releasing Hybrids of Cardiovascular Drugs
Current Medicinal Chemistry Microfluidic Methods for Non-Viral Gene Delivery
Current Gene Therapy Protein Aggregation: Elucidation of the Mechanism and Determination of Associated Thermodynamic and Kinetic Parameters
Current Physical Chemistry Editorial from Editor-in-Chief
Inflammation & Allergy - Drug Targets (Discontinued) Pathophysiological Bases of Eosinophilic Esophagitis Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders
Current Drug Targets - Cardiovascular & Hematological Disorders The Yin and Yang of Antiviral Innate Immunity in Central Nervous System
Current Pharmaceutical Design Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Basic Mechanisms in Atherosclerosis: The Role of Calcium
Medicinal Chemistry Targeting Antibody-Mediated Rejection in the Setting of ABOIncompatible Infant Heart Transplantation: Graft Accommodation vs. B Cell Tolerance
Current Drug Targets - Cardiovascular & Hematological Disorders Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology A Review on Skin Targeted Delivery of Bioactives as Ultradeformable Vesicles: Overcoming the Penetration Problem
Current Drug Targets Influence of Prebiotics on the Human Immune System (GALT)
Recent Patents on Inflammation & Allergy Drug Discovery Antibacterial and Antiinflammatory Properties of Bovine Colostrum
Recent Patents on Inflammation & Allergy Drug Discovery Cubic Phases, Cubosomes and Ethosomes for Cutaneous Application
Current Pharmaceutical Design